AMicale des COXiens
Vous souhaitez réagir à ce message ? Créez un compte en quelques clics ou connectez-vous pour continuer.

AMicale des COXiens

Forum des actionnaires particuliers de NicOx
 
AccueilAccueil  GalerieGalerie  Dernières imagesDernières images  S'enregistrerS'enregistrer  ConnexionConnexion  
Le Deal du moment : -17%
Casque de réalité virtuelle Meta Quest 2 ...
Voir le deal
249.99 €

 

 American Society of Hypertension 25th Annual Scientific Meeting

Aller en bas 
4 participants
AuteurMessage
vinsse

vinsse


Nombre de messages : 515
Date d'inscription : 15/05/2008

American Society of Hypertension 25th Annual Scientific Meeting Empty
MessageSujet: American Society of Hypertension 25th Annual Scientific Meeting   American Society of Hypertension 25th Annual Scientific Meeting Icon_minitimeVen 16 Avr - 12:27

2010 Annual Meeting Program Book American Society of Hypertension 25th Annual Scientific Meeting New

The Journey to Optimal Treatment Strategies for
the OA Patient with Hypertension
Chairperson: Michael A. Weber, MD, Brooklyn, NY
Program Agenda:
6:00 AM Welcome and Introductions
Michael A. Weber, MD
6:10 AM NSAIDs, Blood Pressure and Cardiovascular Risk:
Understanding the Risks for Osteoarthritis Patients
Andrew Whelton, MD, Baltimore, MD
6:30 AM Nitric Oxide: The Journey from Basic Biology to
Therapeutic Potential
Leopoldo Raij, MD, Miami, FL
6:55 AM CINODs: A New Option in the Management of
Osteoarthritis Patients with Hypertension
Michael A. Weber, MD
7:20 AM Panel Discussion/Questions and Answers
All Faculty
Learning Objectives:
• Review the current available options for the
treatment of osteoarthritis (OA) and evaluate
their potential benefits and risks
• Discuss the relationship of background
antihypertensive therapy in NSAID-induced
blood pressure destabilization
• Summarize the outcomes associated with
endothelial dysfunction and decreased
bioavailability of nitric oxide
• Evaluate the data and potential utility of
Cyclooxygenase-Inhibiting Nitric Oxide Donating
(CINOD) drugs
Breakfast will be served at 5:45 AM in the
Trianon Ballroom.


mais nous avons aussi


3 Non-Cardiac Drugs that Raise Blood Pressure
Chairs: Franz Messerli, MD, New York, NY and
Elijah Saunders, MD, Baltimore, MD
Original Communications
6:00 PM OR-9: Hyperuricemia, Cronotherapy with
Alopurinol and Hypertension
Carlos Calvo,1 Alvaro Hermida,1 José Enrique Lopez,1
Marta Pena,1 Luisa Romero,1 Gaila Calvo,1 Antonio
Coca.2 1Hypertension and Vascular Risk Unit.
Complejo Hospitalario Universitario de Santiago,
ES and 2Unit Hypertension, Hospital Clinico de
Barcelona, ES.
6:15 PM OR-10: The Nitric Oxide Donator Naproxcinod Has
Blood Pressure Effects Similar to Placebo in Patients
with Osteoarthritis
W. B. White†,1 T. Schnitzer,2 J. Dijian,3 H. Frayssinet,3
B. Duquesroix,3 M. A. Weber.4 1University of
Connecticut School of Medicine, Farmington, CT,
US; 2Northwestern University Feinberg School of
Medicine, Chicago, IL, US; 3Nicox, S.A., Sophia-
Antipolis, FR and 4SUNY Downstate College of
Medicine, Brooklyn, NY, US.

6:30 PM OR-11: Different Effects of Aliskiren/
Hydrochlorotiazide and Atenolol/
Hydrochlorotiazide Combinations on Central
Pressure in Elderly Hypertensive Patients
Roberto Fogari, Amedeo Mugellini, Paola Preti,
Maurizio Destro, Luca Corradi, Giuseppe Derosa.
Department of Internal Medicine, University of Pavia,
Pavia, IT.
6:45 PM OR-12: Factors Influencing the Ambulatory Blood
Pressure Response to Low-Dose Aspirin in Subjects
with Untreated Mild Hypertension
Diana E. Ayala, Ramon C. Hermida, Maria J. Fontao,
Artemio Mojon, Jose R. Fernandez. University of Vigo,
ES.
7:00 PM Blood Pressure Increases from Non-cardiac
Therapies Including Arthritis Meds, Psychotropics,
Neurological Drugs, Angiogenesis Blockers
Ehud Grossman, MD, Tel Hashomer, Israel

mais encore!!

Targeting Endothelial Dysfunction in Hypertensive
Cardiovascular Disease: Why, When, and How
Chairperson: Thomas D. Giles, MD, New Orleans, LA
Program Agenda:
6:00 AM Introduction: New Evidence for Targeting Critical
Mechanisms in Hypertensive Heart Disease
Thomas D. Giles, MD
6:25 AM Race-Specific Differences in Endothelial
Dysfunction: Relevance to Management of
Hypertension
R. Preston Mason, PhD, Boston, MA
6:50 AM Targeting Endothelial Dysfunction in the
Management of Cardiovascular Disease
Alan H. Gradman, MD, Pittsburgh, PA
7:15 AM Panel Discussion and Concluding Remarks
Thomas D. Giles, MD
Learning Objectives:
• Describe the role of nitric oxide in endothelial
dysfunction and in the pathogenesis of
hypertension, and hypertensive cardiovascular
disease, including LVH and heart failure
• Evaluate the relationship between oxidative stress
and endothelial function and its relevance to the
management of hypertensive patients
• Identify pre-clinical and clinical evidence
supporting the concept that there are race-based
differences in endothelial function which may
have clinical ramifications
• Analyze the pharmacologic differences among
β-blockers, including those with vasodilating
properties, and outline the evidence for the
clinical impact of these properties, especially on
tolerability and efficacy
Breakfast will be served at 5:45 AM in the
Trianon Ballroom.

Désolé encore (que des spécialistes qui ont publiés avec nicox)
7:30 PM – 9:00 PM • Trianon Ballroom
A Cross Examination of Contemporary Issues in
Hypertension: Today’s Controversy and Consensus
Chairperson: George L. Bakris, MD, Chicago, IL
Program Agenda:
7:30 PM Introduction and Opening Remarks
George L. Bakris, MD
7:35 PM Debate #1:
Setting Treatment Goals in Hypertension Care
Domenic A. Sica, MD, Richmond, VA
William B. White, MD, Farmington, CT
8:00 PM Summary Comments/Questions & Answers
Moderated by George L. Bakris, MD
8:05 PM Case Study Discussion: Combining Blood Pressure-
Lowering Agents and Emerging Treatment Options
William B. White, MD
Panel Discussion
All Faculty
8:20 PM Debate #2:
Using Biomarkers to Assess Risk in Hypertension
Patients
Domenic A. Sica, MD
William B. White, MD
8:45 PM Summary Comments/Questions & Answers
Moderated by George L. Bakris, MD
Learning Objectives:
• Optimize cardiovascular risk reduction by
establishing appropriate hypertension treatment
goals and providing blood pressure monitoring
that accurately gauges progress toward treatment
goals
• Improve assessment of individual cardiovascular
risk using biomarkers to guide the development
and adjustment of blood pressure–lowering
regimens
• Develop individualized blood pressure–lowering
regimens that optimally employ currently
available antihypertensive agents, either
individually or in combination
Dinner will be served at 7:30 PM in the

Les posters(connus)
PO-255: 2 Naproxcinod Produces Relaxation in Human
Mammary Arteries Showing Endothelial
Dysfunction
Daniela Miglietta,1 Alessandra Poggi,1 Barbara
Vergani,2 Guido Gelpi,3 Julio Padron,1 Manlio Bolla†.1
1NicOx Research, Bresso, IT; 2MIA Consortium,

PO-1: 3 The Cyclooxygenase Inhibiting Nitric Oxide Donator
(CINOD) Naproxcinod Induces Less Increases in
the 24-Hour Systolic Blood Pressure than Naproxen
and Ibuprofen in Patients with Osteoarthritis and
Hypertension
William B. White†,1 Thomas Schnitzer,2 Pascal
Longlade,3 Rosanna Fleming,3 Jacques Dijian.3
1University of Connecticut School of Medicine,
Farmington, CT, US; 2Northwestern University
Feinberg School of Medicine, Chicago, IL, US and
3Nicox, S.A., Sophia-Antipolis, FR.
Revenir en haut Aller en bas
Invité
Invité




American Society of Hypertension 25th Annual Scientific Meeting Empty
MessageSujet: Re: American Society of Hypertension 25th Annual Scientific Meeting   American Society of Hypertension 25th Annual Scientific Meeting Icon_minitimeVen 16 Avr - 13:06

thks Vinsse comm d'hab !
Revenir en haut Aller en bas
vinsse

vinsse


Nombre de messages : 515
Date d'inscription : 15/05/2008

American Society of Hypertension 25th Annual Scientific Meeting Empty
MessageSujet: Certaines découvertes sont pas mal non plus   American Society of Hypertension 25th Annual Scientific Meeting Icon_minitimeVen 16 Avr - 14:30

rendons à CESAR

http://www.trademarkia.com/dolexcin-77794178.html
allowance issued = autorisation émise 16/03


ps :commmuniqué ou pas de la part de nicox pour ash American Society of Hypertension 25th Annual Scientific Meeting Icon_smile ?
Revenir en haut Aller en bas
Invité
Invité




American Society of Hypertension 25th Annual Scientific Meeting Empty
MessageSujet: Re: American Society of Hypertension 25th Annual Scientific Meeting   American Society of Hypertension 25th Annual Scientific Meeting Icon_minitimeVen 16 Avr - 14:41

Dolexcin me parait parfait comme nom pour le Napro :-)))
Revenir en haut Aller en bas
D@n (Daniel Beldio)

D@n (Daniel Beldio)


Nombre de messages : 3210
Age : 72
Localisation : Pays de l'Arbre et de l'Eau
Date d'inscription : 09/02/2007

American Society of Hypertension 25th Annual Scientific Meeting Empty
MessageSujet: Re: American Society of Hypertension 25th Annual Scientific Meeting   American Society of Hypertension 25th Annual Scientific Meeting Icon_minitimeVen 16 Avr - 14:49

Merci Vinssssssssssssssse ! Wink
Revenir en haut Aller en bas
Invité
Invité




American Society of Hypertension 25th Annual Scientific Meeting Empty
MessageSujet: Re: American Society of Hypertension 25th Annual Scientific Meeting   American Society of Hypertension 25th Annual Scientific Meeting Icon_minitimeVen 16 Avr - 15:01

simis a écrit:
Dolexcin me parait parfait comme nom pour le Napro :-)))

oui et Reliep pour les US, ce serait excellentissime car quitte à me répéter:
relief = soulagement
et p pour pain (douleur)
Revenir en haut Aller en bas
vinsse

vinsse


Nombre de messages : 515
Date d'inscription : 15/05/2008

American Society of Hypertension 25th Annual Scientific Meeting Empty
MessageSujet: c'est mieux en image   American Society of Hypertension 25th Annual Scientific Meeting Icon_minitimeVen 16 Avr - 15:32

American Society of Hypertension 25th Annual Scientific Meeting 20100510
Revenir en haut Aller en bas
JeanCox

JeanCox


Nombre de messages : 1008
Age : 70
Date d'inscription : 19/12/2007

American Society of Hypertension 25th Annual Scientific Meeting Empty
MessageSujet: Re: American Society of Hypertension 25th Annual Scientific Meeting   American Society of Hypertension 25th Annual Scientific Meeting Icon_minitimeVen 16 Avr - 15:32

Merci Vinsse, comme d'habitude, pour ton assiduité et tes trouvailles American Society of Hypertension 25th Annual Scientific Meeting Icon_wink

Quelque chose m'interpelle dans le nom déposé (dans la rubrique Goods and Services) :

pharmaceutical products for the treatment of pain, cardiovascular, rheumatologic and inflammatory diseases

Un peu comme si NicOx savait déjà que la mention serait accordée sur la notice, non ?

Ou est-ce que je prends mes désirs pour la réalité ????
Revenir en haut Aller en bas
Glenmore

Glenmore


Nombre de messages : 331
Age : 56
Localisation : RP 95
Date d'inscription : 29/05/2008

American Society of Hypertension 25th Annual Scientific Meeting Empty
MessageSujet: Re: American Society of Hypertension 25th Annual Scientific Meeting   American Society of Hypertension 25th Annual Scientific Meeting Icon_minitimeVen 16 Avr - 15:50

Merci Vinsse,

Je me demande toujours qui peut assister à des présentations entre 5:45 et 7:30 !!
En tout cas pas les médecins qui ont fait le fête la veille. Wink
L'avenir appartient à ceux qui se lèvent tôt ... et cela se vérifie. American Society of Hypertension 25th Annual Scientific Meeting Icon_geek
Revenir en haut Aller en bas
Invité
Invité




American Society of Hypertension 25th Annual Scientific Meeting Empty
MessageSujet: Re: American Society of Hypertension 25th Annual Scientific Meeting   American Society of Hypertension 25th Annual Scientific Meeting Icon_minitimeVen 16 Avr - 16:11

et encore White page 126 :

Posters
May 2 Sunday Morning
9:00 AM – 6:45 PM • Rhinelander Gallery

Featured Posters – Group 1
Discussants: Lawrence R. Krakoff, MD, Englewood, NJ and
Daniel Levy, MD, Framingham, MA
PO-1: 3 The Cyclooxygenase Inhibiting Nitric Oxide Donator
(CINOD) Naproxcinod Induces Less Increases in
the 24-Hour Systolic Blood Pressure than Naproxen
and Ibuprofen in Patients with Osteoarthritis and
Hypertension
William B. White†,1 Thomas Schnitzer,2 Pascal
Longlade,3 Rosanna Fleming,3 Jacques Dijian.3
1University of Connecticut School of Medicine,
Farmington, CT, US; 2Northwestern University
Feinberg School of Medicine, Chicago, IL, US and

NicOx a la même grandeur de Stand que Novartis et ils sont à côté d'eux .... !


William B. White, MD
Advisor/Consultant: Astellas, Novartis, Takeda, NicOx. Grant/Research
Support: Novartis, NIH. Member, ASH Board of Directors.
3Nicox, S.A., Sophia-Antipolis, FR.
Revenir en haut Aller en bas
D@n (Daniel Beldio)

D@n (Daniel Beldio)


Nombre de messages : 3210
Age : 72
Localisation : Pays de l'Arbre et de l'Eau
Date d'inscription : 09/02/2007

American Society of Hypertension 25th Annual Scientific Meeting Empty
MessageSujet: Re: American Society of Hypertension 25th Annual Scientific Meeting   American Society of Hypertension 25th Annual Scientific Meeting Icon_minitimeVen 16 Avr - 19:05

Dr William B. White ?
Je le mets en poster couleur grand format sur papier glacé à côté de Michele au-dessus de mon bureau si NicOx arrive à ses fins et que la Cox explose ! Razz
Revenir en haut Aller en bas
Contenu sponsorisé





American Society of Hypertension 25th Annual Scientific Meeting Empty
MessageSujet: Re: American Society of Hypertension 25th Annual Scientific Meeting   American Society of Hypertension 25th Annual Scientific Meeting Icon_minitime

Revenir en haut Aller en bas
 
American Society of Hypertension 25th Annual Scientific Meeting
Revenir en haut 
Page 1 sur 1
 Sujets similaires
-
» PRÉSENTATION À L'AMERICAN SOCIETY OF HYPERTENSION 03/05
» NicOx du 12 au 16 juin au congrès de l'European Society of Hypertension
» 20TH European Meeting on Hypertension Oslo June 18-21, 2010 (NicOx présent !)
» 29 Août : European Society of Cardiology à Barcelone avec NicOx !
» Advances in Pharmacologic Modulation of Nitric Oxide in Hypertension.

Permission de ce forum:Vous ne pouvez pas répondre aux sujets dans ce forum
AMicale des COXiens :: Forum public :: Echanges sur NicOx-
Sauter vers: